Description: |
Dose Escalation: RCC with a clear-cell component or non-clear-cell RCC limited to papillary, chromophobe or unclassified histology; advanced or metastatic; measurable dx; at least 1 prior systemic therapy for mets (at least 1 prior cytokine, anti-angiogenic or mTOR inhibitor); MUST have tumor tissue; NO active CNS mets |
|
Link: |
|
|
Site: |
Johns Hopkins Hospital |
|
Principal Investigator: |
Hans Hammers, M.D. |
Overview
Content Tools